DOCSLIB.ORG

ARCH-Vet Anresis.Ch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ARCH-Vet Anresis.Ch Usage of Antibiotics and Occurrence of Antibiotic Resistance in Bacteria from Humans and Animals in Switzerland Joint report 2013 ARCH-Vet anresis.ch Publishing details © Federal Office of Public Health FOPH Published by: Federal Office of Public Health FOPH Publication date: November 2015 Editors: Federal Office of Public Health FOPH, Division Communicable Diseases. Elisabetta Peduzzi, Judith Klomp, Virginie Masserey Design and layout: diff. Marke & Kommunikation GmbH, Bern FOPH publication number: 2015-OEG-17 Source: SFBL, Distribution of Publications, CH-3003 Bern www.bundespublikationen.admin.ch Order number: 316.402.eng Internet: www.bag.admin.ch/star www.blv.admin.ch/gesundheit_tiere/04661/04666 Table of contents 1 Foreword 4 Vorwort 5 Avant-propos 6 Prefazione 7 2 Summary 10 Zusammenfassung 12 Synthèse 14 Sintesi 17 3 Introduction 20 3.1 Antibiotic resistance 20 3.2 About anresis.ch 20 3.3 About ARCH-Vet 21 3.4 Guidance for readers 21 4 Abbreviations 24 5 Antibacterial consumption in human medicine 26 5.1 Hospital care 26 5.2 Outpatient care 31 5.3 Discussion 32 6 Antibacterial sales in veterinary medicines 36 6.1 Total antibacterial sales for use in animals 36 6.2 Antibacterial sales – pets 37 6.3 Antibacterial sales – food producing animals 38 6.4 Discussion 40 7 Resistance in bacteria from human clinical isolates 42 7.1 Escherichia coli 42 7.2 Klebsiella pneumoniae 44 7.3 Pseudomonas aeruginosa 48 7.4 Acinetobacter spp. 49 7.5 Streptococcus pneumoniae 52 7.6 Enterococci 54 7.7 Staphylococcus aureus 55 Table of contents 1 8 Resistance in zoonotic bacteria 58 8.1 Salmonella spp. 58 8.2 Campylobacter spp. 61 9 Resistance in indicator bacteria in animals 68 9.1 Enterococci 68 9.2 Escherichia coli 72 9.3 ESBL / pAmpC-producing Escherichia coli 76 9.4 Methicillin resistant Sta phy lococcus aureus (MRSA) 81 10 Resistance in diagnostic submissions from animals 86 10.1 Staphylococcus spp. 86 11 Materials and methods 92 11.1 Data on Antibacterial consumption in human medicine 92 11.2 Data on antibacterial sales in veterinary medicine 92 11.3 Bacterial isolates from humans (clinical probes) 93 11.4 Bacterial isolates from animals (for monitoring: clinical and not clinical probes) 93 11.5 Susceptibility testing, breakpoints, processing antibiotic resistance data from human isolates 94 11.6 Susceptibility testing, cut-off, processing anti biotic resistance data from animal isolates 95 Annex I 100 Defined daily dose (DDD) of antibiotics for patient treatment Annex II 104 Distribution of minimal inhibitory concentrations (MICs) in bacterial isolates from animals Annex III 114 Tables of multi-resistance patterns in bacterial isolates from animals Annex IV 128 anresis.ch participants and steering committee Index 131 Figures, tables and textboxes 2 Table of contents 1 Foreword Antibacterial consumption in human medicine 3 1 Foreword Antibiotic resistance is an emerging global public health a system to enable the continuous monitoring of resistance threat. The use of antibiotics contributes to the selection of in farm animals, meat and dairy products in Switzerland. Ad- resistant bacteria leading to treatment failure of bacterial dis- ditionally it compiles data on sales of antimicrobial agents for eases in humans and animals. Resistant bacteria can spread veterinary medicine. Since 2009 data on sales of veterinary between humans in the community and healthcare. On the antimicrobials and results of the monitoring of resistance in other hand, resistant bacteria from animals and the environ- farm animals are published yearly in the ARCH-Vet report. ment can be transmitted to humans either through direct The present report, which is the first joint report from anre- contact or through ingestion of contaminated food or other sis.ch and ARCH-Vet, presents Swiss data for 2013. In addi- contaminated vehicles. Increasing global trade and travel tion to resistance data it includes data on the consumption favor additionally the spread of antimicrobial resistance be- of antibiotics in humans and sales of antimicrobials in veter- tween countries and continents. Regarding the complexity inary medicine. It is the basis for the detection, interpreta- of the epidemiology of antimicrobial resistance, it is impor- tion and evaluation of trends regarding usage of antibiotics tant to monitor trends in antibiotic resistance in a holistic and occurrence of resistance. Although the data for human approach (“One Health approach”) including data on usage and veterinary medicine are presented in one report, it is and resistance in human and veterinary medicine as well as important to be aware that differences between the moni- in food production. toring systems for collection, interpretation and reporting In response to the growing concern about antibiotic resist- hamper direct comparisons of the results. Cooperation and ance, the Ministries of home and economic affairs assigned coordination between the different monitoring-networks the Federal Office of Public Health (FOPH), the Food Safety have to be strengthened and refined to improve comparabil- and Veterinary Office (FSVO), the Federal Office for Agricul- ity and fill the gaps, as it is foreseen in the national strategy ture (FOAG) and the Federal Office for the Environment on antimicrobial resistance (StAR). (FOEN) to develop and implement a national strategy to combat antibiotic resistance (“Strategie Antibiotikaresisten- The editors would like to thank all those who contributed to zen, StAR”). The approval by the Federal Council is planned data collection and the writing of this report for their excel- for the end of 2015. The strategy will encompass all the ac- lent work. tion fields of the different sectors (regulatory, prudent use, surveillance, research, control in hospitals etc.). The global goal of the strategy is to ensure the long-term efficacy of antibiotics in preserving human and animal health. It empha- sizes the importance of monitoring antimicrobial drug usage and resistance in both human and veterinary medicine. The first National Research ”Antibiotic Resistance” (NRP 49) in Switzerland was approved in 1999 and ran between 2001 and 2006. A very important achievement of this pro- gram was the establishment of a surveillance system for human medicine (anresis.ch). Since 2004, anresis.ch has been collecting routine antibiotic resistance data from hu- man microbiology laboratories. The system has been further developed and at present, it also monitors data on human antibiotic consumption (hospitals and outpatient). The NRP 49 also provided the basis for a monitoring pro- gram in veterinary medicine. In 2006, the FSVO introduced Daniel Koch Josef Schmidt Division Communicable Diseases Division Animal Health Federal Office of Public Health Federal Food Safety and Veterinary Office 4 Foreword 1 Vorwort Antibiotikaresistenzen sind ein globales Problem und bedro- bio logischen Laboratorien. Das System wurde dann weiter- hen die öffentliche Gesundheit weltweit. Die Verwendung entwickelt und überwacht nun auch die Daten zum mensch- von Antibiotika trägt zur Selektion resistenter Bakterien bei, lichen Antibiotikakonsum (Spitäler und ambulanter Bereich). was zu Behandlungsversagen bei bakteriellen Erkrankungen Das NFP 49 bildete auch die Grundlage für ein Monitoring- von Mensch und Tier führt. Resistente Bakterien können programm in der Veterinärmedizin. 2006 führte das BLV ein sich einerseits zwischen Menschen in der Bevölkerung und System ein, um in der Schweiz ein kontinuierliches Antibio- in Gesundheitseinrichtungen ausbreiten. Andererseits kön- tikaresistenzmonitoring bei Nutztieren, Fleisch und Milch- nen resistente Bakterien von Tieren und aus der Umwelt produkten zu ermöglichen. Zusätzlich trägt es Daten zum entweder durch direkten Kontakt oder durch kontaminierte Vertrieb von Antibiotika in der Veterinärmedizin zusammen. Lebensmittel oder andere Trägerstoffe auf Menschen über- Seit 2009 werden die Daten zum Vertrieb von Veterinäranti- tragen werden. Zunehmender globaler Handel und Reiseak- biotika und die Ergebnisse des Antibiotikaresistenzmonito- tivitäten fördern zusätzlich die Verbreitung von Antibiotikare- rings bei Nutztieren jährlich im ARCH-Vet Bericht veröffent- sistenzen über Länder und Kontinente hinweg. Angesichts licht. der komplexen Epidemiologie von Antibiotikaresistenzen ist Das vorliegende Dokument, bei dem es sich um den ersten es wichtig, Trends bei resistenten Bakterien nach einem gemeinsamen Bericht von anresis.ch und ARCH-Vet han- ganzheitlichen Ansatz («One Health Approach») zu überwa- delt, präsentiert Schweizer Daten für das Jahr 2013. Zusätz- chen und Daten zur Antibiotikaverwendung und Resistenz- lich zu den Resistenzdaten umfasst er Daten zum menschli- lage aus der Human- und Veterinärmedizin sowie der Le- chen Verbrauch antibiotischer Wirkstoffe und zum Vertrieb bensmittelproduktion einzubeziehen. von Antibiotika in der Veterinärmedizin. Er bildet die Grund- Als Reaktion auf die wachsende Besorgnis bezüglich Anti- lage für die Erkennung, Interpretation und Evaluation von biotikaresistenzen erteilten die Eidgenössischen Departe- Trends bezüglich Verwendung antibiotischer Wirkstoffe und mente des Innern (EDI) und für Wirtschaft, Bildung und For- Auftreten von Resistenzen. Obwohl die Daten der Human- schung (WBF) den Bundesämtern für Gesundheit (BAG), für und der Veterinärmedizin in einem Bericht erscheinen, gilt Lebensmittelsicherheit und Veterinärwesen (BLV), für Land- es zu beachten, dass die Überwachungssysteme Unter- wirtschaft (BLW) und für Umwelt (BAFU)
Load more

Recommended publications
  • Survey of Tiamulin+Oxytetracyclinein Control of CRD Complex Due to La Sota Vaccine in Broiler Chickens
    Available online a t www.scholarsresearchlibrary.com Scholars Research Library European Journal of Zoological Research, 2013, 2 (4): 45-49 (http://scholarsresearchlibrary.com/archive.html) ISSN: 2278–7356 Survey of Tiamulin+Oxytetracyclinein control of CRD complex due to La Sota vaccine in broiler chickens Adel Feizi Department of Clinical Sciences, Tabriz Branch, Islamic Azad University, Tabriz, Iran _____________________________________________________________________________________________ ABSTRACT Mycoplasma gallisepticum (MG) is one of the most important diseases of poultry industry in Iran and all over the world. Mortality, poor weight gain and increasing of feed conversion ratio (FCR) were seen in MG infected flocks. Several drugs are used for prevention and control of MG, the purpose of this study was to investigateoxytetracycline + Tiamulinefficacy on MG, and its role on broilers performance.In this study, 240 Ross 308 broilers divided in 2 groups. In one of the groups, oxytetracycline + Tiamulinwere used in days 21 to 30 following La Sota vaccination for controlling vaccination reaction and in the secondgroup, placebo was used and that group mentioned as a control group. Gross lesions, mortality, and growth parameters include body weight gain,feed intake and FCR were calculated in all groups weekly after 21 st day.Results showed that in treatment groups mortality percent was significantly (p<0.05) lower than control group and pericarditis, perihepatitis and airsacculitis was sever in control groups in comparison to antibiotic treated groups. Also body weight and FCR was significantly were different between control group and oxytetracycline + Tiamulin group (p<0.05).It can be concluded that usage of these antibiotics simultaneously could prevent vaccination reaction due to La Sota vaccine and also following MG complications, economical losses in poultry and finally it can be improve broilers performance Key words: Vaccination Reaction, Mycoplasma Gallisepticum, Oxytetracycline, Tiamulin, Ross 308.
    [Show full text]
  • Simultaneous Determination of Amoxicillin and Clavulanic Acid in Pharmaceutical Preparations by Capillary Zone Electrophoresis
    Brazilian Journal of Pharmaceutical Sciences vol. 52, n. 2, apr./jun., 2016 Article http://dx.doi.org/10.1590/S1984-82502016000200006 Simultaneous determination of amoxicillin and clavulanic acid in pharmaceutical preparations by capillary zone electrophoresis Gabriel Hancu1,*, Anamaria Neacşu1, Lajos Attila Papp1, Adriana Ciurba2 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy, TîrguMureş, Romania, 2Department of PharmaceuticalTechnology, Faculty of Pharmacy, University of Medicine and Pharmacy, Tîrgu Mureş, Romania Clavulanic acid enhances the antibacterial spectrum of amoxicillin by rendering most β-lactamase producing isolates susceptible to the drug. A fast, simple and efficient capillary electrophoresis method was developed for the simultaneous determination of amoxicillin and clavulanic acid from complex mixtures. Using a 25 mM sodium tetraborate as background electrolyte at a pH of 9.30, + 25 kV applied voltage, 25 °C system temperature, UV determination at 230 nm; we succeeded in simultaneous separation of amoxicillin and clavulanic acid in approximately 2 minutes. The analytical performance of the method was evaluated in terms of reproducibility, precision, accuracy, and linearity. The optimized analytical method was applied for the determination of the two analytes from combined commercial pharmaceutical preparations. This CE method is fast, inexpensive, efficient, and environmentally friendly when compared with the more frequently used high performance liquid chromatography methods described in the literature. Uniterms: Amoxicillin/determination. Clavulanic acid/determination. Capillary electrophoresis/ quantitative analysis. Antibacterials/quantitative analysis. O ácido clavulânico acentua o espectro antibacteriano de amoxicilina, tornando a maioria dos isolados produtores de β-lactamase sensíveis ao fármaco. Desenvolveu-se um método rápido, simples e eficiente de electroforese capilar (EC) para a determinação simultânea de amoxicilina e de ácido clavulânico a partir de misturas complexas.
    [Show full text]
  • A Diverse Intrinsic Antibiotic Resistome from a Cave Bacterium
    ARTICLE Received 5 Jul 2016 | Accepted 1 Nov 2016 | Published 8 Dec 2016 DOI: 10.1038/ncomms13803 OPEN A diverse intrinsic antibiotic resistome from a cave bacterium Andrew C. Pawlowski1, Wenliang Wang1, Kalinka Koteva1, Hazel A. Barton2, Andrew G. McArthur1 & Gerard D. Wright1 Antibiotic resistance is ancient and widespread in environmental bacteria. These are there- fore reservoirs of resistance elements and reflective of the natural history of antibiotics and resistance. In a previous study, we discovered that multi-drug resistance is common in bacteria isolated from Lechuguilla Cave, an underground ecosystem that has been isolated from the surface for over 4 Myr. Here we use whole-genome sequencing, functional genomics and biochemical assays to reveal the intrinsic resistome of Paenibacillus sp. LC231, a cave bacterial isolate that is resistant to most clinically used antibiotics. We systematically link resistance phenotype to genotype and in doing so, identify 18 chromosomal resistance elements, including five determinants without characterized homologues and three mechanisms not previously shown to be involved in antibiotic resistance. A resistome comparison across related surface Paenibacillus affirms the conservation of resistance over millions of years and establishes the longevity of these genes in this genus. 1 Michael G. DeGroote Institute for Infectious Disease Research and the Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada L8S 4K1. 2 Department of Biology, University of Akron, Akron, Ohio 44325, USA. Correspondence and requests for materials should be addressed to G.D.W. (email: [email protected]). NATURE COMMUNICATIONS | 7:13803 | DOI: 10.1038/ncomms13803 | www.nature.com/naturecommunications 1 ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13803 nderstanding the evolution and origins of antibiotic rhizophila (formerly identified as Micrococcus luteus) resistance genes is vital to predicting, preventing and (Supplementary Tables 1 and 2).
    [Show full text]
  • Swedres-Svarm 2010
    SVARM|2010 Swedish Veterinary Antimicrobial Resistance Monitoring Content Swedish Veterinary Antimicrobial Resistance Monitoring 2010 Preface .............................................................................................3 Guidance for readers ........................................................................4 Editors Summary ..........................................................................................5 Björn Bengtsson, Helle Ericsson Unnerstad, Sammanfattning...............................................................................7 Christina Greko, Ulrika Grönlund Andersson and Annica Landén Use of antimicrobials .......................................................................9 Department of Animal Health and Zoonotic bacteria ...........................................................................14 Antimicrobial Strategies, National Veterinary Salmonella ...................................................................................14 Institute (SVA) SE-751 89 Uppsala, Sweden Campylobacter .............................................................................18 Methicillin resistant Staphylococcus aureus (MRSA) ....................19 Authors Highlight: Escherichia coli with ESBL - or transferrable Björn Bengtsson, Helle Ericsson Unnerstad, AmpC-type resistance in broilers .............................................22 Christina Greko, Ulrika Grönlund Andersson and Annica Landén Indicator bacteria ...........................................................................24
    [Show full text]
  • Farrukh Javaid Malik
    I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent.
    [Show full text]
  • DANMAP 2016 - Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria from Food Animals, Food and Humans in Denmark
    Downloaded from orbit.dtu.dk on: Oct 09, 2021 DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark Borck Høg, Birgitte; Korsgaard, Helle Bisgaard; Wolff Sönksen, Ute; Bager, Flemming; Bortolaia, Valeria; Ellis-Iversen, Johanne; Hendriksen, Rene S.; Borck Høg, Birgitte; Jensen, Lars Bogø; Korsgaard, Helle Bisgaard Total number of authors: 27 Publication date: 2017 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Borck Høg, B. (Ed.), Korsgaard, H. B. (Ed.), Wolff Sönksen, U. (Ed.), Bager, F., Bortolaia, V., Ellis-Iversen, J., Hendriksen, R. S., Borck Høg, B., Jensen, L. B., Korsgaard, H. B., Pedersen, K., Dalby, T., Træholt Franck, K., Hammerum, A. M., Hasman, H., Hoffmann, S., Gaardbo Kuhn, K., Rhod Larsen, A., Larsen, J., ... Vorobieva, V. (2017). DANMAP 2016 - Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Statens Serum Institut, National Veterinary Institute, Technical University of Denmark National Food Institute, Technical University of Denmark. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • NEW ANTIBACTERIAL DRUGS Drug Pipeline for Gram-Positive Bacteria
    NEW ANTIBACTERIAL DRUGS Drug pipeline for Gram-positive bacteria Françoise Van Bambeke, PharmD, PhD Paul M. Tulkens, MD, PhD Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium http://www.facm.ucl.ac.be Based largely on presentations given at the 24th and 25th European Congress of Clinical Microbiology and Infectious Diseases and the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 1 Disclosures Research grants for work on investigational compounds discussed in this presentation from • Cempra Pharmaceuticals • Cerexa • GSK • Melinta therapeutics • The Medicine Company • MerLion Pharmaceuticals • Theravance • Trius 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 2 Belgium 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 3 Belgium 10 millions inhabitants … 10 Nobel prizes (10/850) • Peace - Institute of International Law, Ghent (1904) - Auguste Beernaert (1909) - Henri Lafontaine (1913) - Father Dominique Pire (1958) • Literature - Maurice Maeterlinck, Ghent (1911) • Medicine - Jules Bordet, Brussels (1919) - Corneille Heymans, Ghent (1938) - Christian de Duve, Louvain (1974) - Albert Claude, Brussels (1974) • Chemistry - Ilya Prigogyne, Brussels (1977) - Physics - François Englert, Brussels (2013) 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 4 The Catholic University of Louvain in brief (1 of 4) • originally founded in 1425 in the city of Louvain (in French and English; known as Leuven in Flemish) 22/05/2015 Gause Institute for New Antibiotics: the anti-Gram positive pipeline 5 The Catholic University of Louvain in brief (2 of 4) • It was one of the major University of the so-called "Low Countries" in the 1500 – 1800 period, with famous scholars and discoverers (Vesalius for anatomy, Erasmus for philosophy, …).
    [Show full text]
  • Clinical Pharmacology of Ampicillin in Infants and Children
    Central Journal of Drug Design and Research Bringing Excellence in Open Access Review Article *Corresponding author Gian Maria Pacifici,Associate professorof Pharmacology,via Sant’Andrea 32,56127 Pisa,Italy. Clinical Pharmacology of Email: [email protected] Submitted: 19 April 2021 Accepted: 25 April 2021 Ampicillin in Infants and Published: 27 April 2021 ISSN: 2379-089X Children Copyright © 2021 Pacifici GM Gian Maria Pacifici* OPEN ACCESS Associate professorof Pharmacology, Italy Keywords Abstract • Ampicillin • Dosing Ampicillin is an aminopenicillin and is more active than penicillin G. Ampicillin is destroyed by β-lactamase • Treatment and is co-formulated with sulbactam an inhibitor of β-lactamase. Ampicillin is bactericidal and it is active • Trials against meningococci, Listeria monocytogenes, enterococci, and the co-administration with sulbactam markedly • Placental-transfer expands the spectrum of activity against Haemophilus influenzae, Escherichia coli, Proteus, and Bacillus fragilis. • Breast-milk Ampicillin may be administered intravenously and orally and the intravenous dose is 50 mg twice-daily and • Meningitis thrice-daily in preterm and term infants, respectively. The oral dose in children ranges from 125 to 500 mg 4 times-daily and increases with the chid age. Ampicillin has been found efficacy and safe in infants and children but may cause adverse-effects. In infants, the ampicillin elimination half-life ranges between 2.4 to 5.0 hours and decreases with infant maturation and in children it is about 0.8 hours. Ampicillin interacts with drugs, the treatment and the trials with ampicillin have been extensively studied in infants and children. This antibiotic freely crosses the human placenta but poorly migrates into the breast-milk.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries
    Original Investigation | Global Health Evaluation of the Coverage of 3 Antibiotic Regimens for Neonatal Sepsis in the Hospital Setting Across Asian Countries Julia A. Bielicki, MD; Mike Sharland, MD; Paul T. Heath, FRCPCH; A. Sarah Walker, PhD; Ramesh Agarwal, MD; Paul Turner, PhD; David A. Cromwell, PhD Abstract Key Points Question What is the antibiotic IMPORTANCE High levels of antimicrobial resistance in neonatal bloodstream isolates are being coverage offered by empirical neonatal reported globally, including in Asia. Local hospital antibiogram data may include too few isolates to sepsis treatment with aminopenicillin- meaningfully examine the expected coverage of antibiotic regimens. gentamicin, third-generation cephalosporins (cefotaxime or OBJECTIVE To assess the coverage offered by 3 antibiotic regimens for empirical treatment of ceftriaxone), and meropenem in Asian neonatal sepsis in Asian countries. countries? DESIGN, SETTING, AND PARTICIPANTS A decision analytical model was used to estimate coverage Findings In this decision analytical of 3 prespecified antibiotic regimens according to a weighted-incidence syndromic combination model based on a decision tree, 8376 antibiogram. Relevant data to parameterize the models were identified from a systematic search of isolates from 10 countries were used to Ovid MEDLINE and Embase. Data from Asian countries published from 2014 onward were of interest. estimate coverage. Meropenem Only data on blood culture isolates from neonates with sepsis, bloodstream infection, or bacteremia generally had the highest coverage reported from the relevant setting were included. Data analysis was performed from April 2019 to (from 64.0% in India to 90.6% in July 2019. Cambodia) followed by aminopenicillin- gentamicin (from 35.9% in Indonesia to EXPOSURES The prespecified regimens of interest were aminopenicillin-gentamicin, third- 81.0% in Laos) and cefotaxime or generation cephalosporins (cefotaxime or ceftriaxone), and meropenem.
    [Show full text]